| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Zai Lab Limited$18.27
+0.06 (+0.33%)
B 70Pipeline Score Undervalued Biotech · Commercial
Market Cap
2.12 B
EPS
-1.62
P/E Ratio
-
Value Trade
10.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
99.61 M
R&D Expenses
65.59 M
Operating CF
-11.91 M
Total Assets
1.10 B
Total Liabilities
433.76 M
Equity
661.98 M
D/E Ratio
12,345
-9.04 %
Week
-23 %
1 Month
-6.34 %
3 Month
-5.34 %
6 Month
-88.53 %
5 Year
-23.26 %
All Time
Cash Data
Cash Position
661.32 M
Monthly Burn
3.97 M
Runway
163.8 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
353.71 K
52 Week Range
15.96 - 44.34
% held by Insiders
6.87 %
% held by Institutions
24.03 %
Enterprise Value
1.59 B
Total Shares
112.55 M
Short %
6.04 %
Float Shares
110.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zai Lab Limited
568Total events
14Upcoming
272Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutefgartigimodApprovedClinical Data
Subscribe to view catalyst details
TBD
◆Enrollment CompleteElegrobartTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-10-24 | ZL-1310 (investigational antibody-drug conjugate) | Phase 1 readout | Phase 1 | — | – | – | – |
2024-10-24 | ZL-1310 (investigational antibody-drug conjugate) | Phase 1 readout | Phase 1 | — | – | – | – |
2024-10-24 | ZL-1310 (investigational antibody-drug conjugate) | Phase 1 readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
B70
Pipeline Score $7.5B
Pipeline ValueUndervalued
Valuation Signal18
Drugs Scored3.5x
rNPV / MCap Top 94%
Small Cap (rank 56 of 913)
Percentile RankZai Lab Limited holds a solid B-grade pipeline (70/100), with $11.5B risk-adjusted pipeline value, led by ZL-1211 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZL-1211 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05065710 | 10% | $5.3B | COMPLETED | 34 | - | - | Apr 9, 2024 | - | Sep 3, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zocilurtatug pelitecan Fast Track | extensive stage small cell lung cancer with brain metastases | Phase 1 | 2026-04-20 | intracranial regression: significant; objective response rate: 38.2% Read More | Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas Read More | |
zocilurtatug pelitecan Fast Track | extensive stage small cell lung cancer with brain metastases | Phase 1 | 2026-04-20 | intracranial regression: significant; objective response rate: 38.2% Read More | Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas Read More | |
zocilurtatug pelitecan Fast Track | extensive stage small cell lung cancer with brain metastases | Phase 1 | 2026-04-20 | intracranial regression: significant; objective response rate: 38.2% Read More | Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZLAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZLAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZLABZai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Zai Lab Limited will report its second quarter 2026 financial results on August 6, 2026. The announcement will occur before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. This event will provide insights into the company's recent corporate developments.
Read more →ZLABZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Zai Lab has been granted orphan drug designation by the European Medicines Agency for Zocilurtatug Pelitecan, aimed at treating pulmonary neuroendocrine carcinomas. This designation is expected to facilitate the drug's development and potential approval in the European market. The orphan status highlights the drug's significance for rare diseases.
Read more →ZLABZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab has received approval from China's NMPA for TIVDAK (tisotumab vedotin) to treat adult patients with recurrent or metastatic cervical cancer. This approval follows the successful results of the Phase 3 innovaTV 301 clinical trial. TIVDAK is indicated for patients who have experienced disease progression after chemotherapy.
Read more →ZLABargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Read more →ZLABVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Read more →ZLABZai Lab Announces Changes to Senior Leadership Team - May 21, 2026
Zai Lab Limited announced changes to its senior leadership team, including the departure of President and COO Josh Smiley. The company aims to enhance operational performance and efficiency. Zai Lab is also preparing for significant clinical data readouts in 2026 and the launch of COBENFY™ in China, alongside multiple regional regulatory approvals.
Read more →ZLABZai Lab Announces Changes to Senior Leadership Team
Zai Lab has announced changes to its senior leadership team. The article does not provide specific details about the changes or their implications for the company. This announcement may indicate a strategic shift within the organization. Further information is needed to assess the impact of these leadership changes.
Read more →ZLAB▲ +5.3%on this news
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Zai Lab has been granted Fast Track designation by the U.S. FDA for its investigational drug, Zocilurtatug Pelitecan (Zoci). This drug is a DLL3-targeting antibody-drug conjugate aimed at treating extrapulmonary neuroendocrine carcinomas (epNECs). The designation is expected to facilitate faster development and review of the drug.
Read more →ZLAB▼ -5.9%on this newsshared move
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Read more →ZLAB▼ -5.9%on this newsshared move
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Limited reported its financial results for Q1 2026, highlighting a decrease in total revenue to $99.6 million, down 6% year-over-year. Despite challenges, the company made significant advancements in its oncology pipeline, particularly with zoci, and is preparing for the launch of KarXT in China. The company also noted increased R&D expenses and a net loss of $51 million, reflecting ongoing investments in its clinical programs.
Read more →ZLABViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Read more →ZLAB▼ -6.4%on this news
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited will report its first quarter 2026 financial results on May 7, 2026. The announcement will occur before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. Participants must register in advance to join the call, which will also be available for replay afterward.
Read more →ZLABZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Zai Lab has presented promising preclinical data for ZL-1503, a bispecific antibody targeting IL-13 and IL-31Rα, at the IMMUNOLOGY2026 conference. The data indicate that ZL-1503 could provide rapid itch relief and reduce inflammation in atopic diseases. The antibody demonstrated significant efficacy in suppressing symptoms over 112 days and has a favorable safety profile, supporting its advancement to Phase 1/1b clinical trials.
Read more →ZLABZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Zai Lab has announced promising clinical data for zocilurtatug pelitecan (zoci), an antibody-drug conjugate targeting DLL3, showing rapid intracranial responses in patients with extensive stage small cell lung cancer (ES-SCLC) and brain metastases. The ongoing Phase 1 trial demonstrates significant tumor regression, while additional data suggests activity in other neuroendocrine carcinomas. Zai Lab plans to present these findings at the AACR Annual Meeting 2026.
Read more →ZLAB▲ +5.9%on this newsshared move
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Boehringer Ingelheim and Zai Lab have initiated a clinical collaboration to evaluate a dual DLL3-targeting therapy for small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). The Phase Ib/II study will assess the safety and clinical activity of combining obrixtamig, a T-cell engager, with Zai Lab's zocilurtatug pelitecan, an antibody-drug conjugate. This collaboration aims to provide more effective treatment options for patients in need.
Read more →ZLAB▲ +8.1%on this news
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Zai Lab has announced a global clinical trial collaboration with Amgen to evaluate zocilurtatug pelitecan, a DLL3-targeting ADC, in combination with Amgen's IMDELLTRA therapy for extensive-stage small cell lung cancer. The Phase 1b study will assess the safety and efficacy of this combination. Zai Lab retains ownership of zoci and will supply the drug for the study.
Read more →ZLABViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Read more →ZLABZai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Zai Lab will present data on three investigational oncology therapies at AACR 2026, including zocilurtatug pelitecan (Zoci), which targets DLL3 in small-cell lung cancer. The other candidates, ZL-6201 and ZL-1222, focus on sarcoma and immunotherapy, respectively. These presentations underscore Zai Lab's commitment to innovative cancer treatments.
Read more →ZLABVertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
Read more →ZLABZai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Zai Lab Limited reported its fourth quarter and full-year 2025 financial results, showcasing significant advancements in its product pipeline and commercial business. The company highlighted strong sales growth across several products, including ZEJULA and XACDURO. Zai Lab is strategically focusing on late-stage immunology and oncology programs for 2026, alongside new collaborations to enhance market access.
Read more →ZLABargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Read more →ZLABU.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Read more →ZLABZai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
Zai Lab Limited will announce its fourth quarter and full year 2025 financial results on February 26, 2026. The announcement will precede a conference call and webcast at 8:00 a.m. ET. Participants are required to register in advance to access the call. Zai Lab is committed to developing innovative biopharmaceutical products.
Read more →ZLABZai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
Zai Lab Limited provided an update on its strategic priorities and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company is advancing its lead asset, Zoci, into Phase 3 trials and has a strong portfolio of commercial products in China. Zai Lab's dual-engine model supports both immediate performance and long-term growth, with multiple key milestones expected in 2026.
Read more →ZLABZai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
Read more →ZLABZai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
Zai Lab Limited has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2026. Senior management will present at 3:00 p.m. PST / 6:00 p.m. EST, with a live webcast available on the company's Investor Relations page. An archived replay will be accessible for 30 days post-event.
Read more →ZLAB▲ +6.3%on this news
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Zai Lab has received approval from China's NMPA for COBENFY, a novel therapy for schizophrenia. This marks a significant advancement in treatment options, as it is the first new therapy in over 70 years. COBENFY targets M1 and M4 receptors, providing a new approach to managing schizophrenia symptoms. The approval is supported by extensive clinical trial data, indicating its potential to improve patient outcomes in China.
Read more →ZLABargenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Read more →ZLABZai Lab Announces Updates to China’s National Reimbursement Drug List
Zai Lab Limited announced the renewal of VYVGART, NUZYRA, and ZEJULA in China's National Reimbursement Drug List for 2025. This renewal enhances patient access to these innovative therapies, reflecting their clinical value. Zai Lab aims to continue improving the affordability and accessibility of its medicines in Greater China.
Read more →ZLABZai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Read more →ZLABVertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
Read more →ZLABZai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
Zai Lab reported a 14% increase in revenues for Q3 2025, reaching $116.1 million, while improving its operating loss by 28%. The company highlighted promising data for Zocilurtatug pelitecan in extensive-stage small cell lung cancer and announced the initiation of a global Phase 1 study for ZL-1503. Additionally, KarXT has been included in China's national treatment guidelines for schizophrenia, marking a significant milestone for the company.
Read more →ZLAB▼ -6.7%on this newsshared move
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates - Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first-
Zai Lab announced strong financial results for the third quarter of 2025, with a 14% year-over-year increase in total revenues to $116.1 million. Key highlights include the initiation of a global registrational study for Zocilurtatug pelitecan in extensive-stage small cell lung cancer and advancements in other pipeline programs. Notably, KarXT was included in China's national schizophrenia treatment guidelines, underscoring its potential. Despite improvements in operating losses, Zai Lab faces challenges with product sales, particularly for ZEJULA amid competitive pressures.
Read more →ZLABUpdate on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study
Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study
Read more →ZLABZai Lab Announces Participation in Investor Conferences in November and December 2025
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Read more →ZLAB▼ -6.1%on this news
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Read more →ZLABZai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Read more →ZLABZai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Read more →ZLABZai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Recepto
Zai Lab announced positive interim results from the Phase 3 FORTITUDE-101 trial, showing that bemarituzumab plus chemotherapy significantly improves overall survival in patients with FGFR2b-positive gastric cancer. This marks a significant advancement as there are currently no approved therapies targeting FGFR2b overexpression in gastric cancer in China. The company plans to expedite regulatory submission based on these results.
Read more →ZLABVertex Announces Key Advancements Across Kidney Portfolio
Vertex Announces Key Advancements Across Kidney Portfolio
Read more →ZLABUpdate on Amgen’s bemarituzumab Phase 3 FORTITUDE-101 Study
Amgen has completed the final analysis of the Phase 3 FORTITUDE-101 trial for bemarituzumab in gastric cancer. While the interim analysis showed significant survival benefits, the final results indicated a reduced effect. Zai Lab plans to wait for the FORTITUDE-102 trial results before proceeding with regulatory filings, expected by mid-2026.
Read more →ZLABZai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
Read more →ZLABZai Lab Announces Participation in Investor Conferences in September 2025
Zai Lab Announces Participation in Investor Conferences in September 2025
Read more →ZLABargenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Read more →ZLABZai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
Read more →ZLABZai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
Zai Lab reported a 9% year-over-year revenue increase to $110 million for Q2 2025, with VYVGART achieving record patient utilization. The company improved its operating loss by 28% and reaffirmed its full-year revenue guidance. Key pipeline developments include promising data for ZL-1310 and bemarituzumab, with regulatory submissions expected in the latter half of 2025.
Read more →ZLABZai Lab Establishes Oncology Scientific Advisory Board
Zai Lab Establishes Oncology Scientific Advisory Board
Read more →ZLAB▼ -12%on this news
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates - Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025 reaffirming full-year 2025 revenue guidance of $560 mil
Zai Lab reported its second quarter 2025 financial results, revealing a 9% year-over-year growth in total revenues, reaching $110 million. The company reaffirmed its full-year revenue guidance of $560 million to $590 million. Notably, VYVGART demonstrated record patient utilization in clinical settings. Several promising clinical trial updates were shared, including favorable results for bemarituzumab as a first-line treatment for gastric cancer. Despite positive developments, Zai Lab still faced a substantial operating loss and declining sales of certain products.
Read more →ZLABZai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
Read more →ZLABZai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Read more →ZLABZai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
Read more →ZLABZai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Read more →ZLABZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Read more →ZLABZai Lab Announces Participation in Investor Conferences in June 2025
Zai Lab Announces Participation in Investor Conferences in June 2025
Read more →ZLABZai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
Zai Lab reported a 22% increase in total revenues for Q1 2025, reaching $106.5 million. The company also noted a significant improvement in operating loss, which declined by 20% year-over-year. Zai Lab is advancing its oncology pipeline with upcoming presentations at ASCO 2025 and has reaffirmed its full-year revenue guidance. Despite a net loss of $48.4 million, the company maintains a strong cash position.
Read more →ZLAB▲ +6.7%on this newsshared move
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
Read more →ZLABZai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates - Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025 reaffirming full-year 2025 revenue guidance of $560 mill
Zai Lab (ZLAB) announced its financial results for the first quarter of 2025, reporting a 22% increase in total revenues, which reached $106.5 million. The company improved its operating loss significantly, showing a 20% decline year-over-year. Zai Lab also reaffirmed its full-year revenue guidance and is on track to achieve profitability by the fourth quarter of 2025. The advancement of its pipeline, notably ZL-1310 for small cell lung cancer, was highlighted as a key focus along with maintaining a strong cash position.
Read more →ZLABZai Lab Complies with the HFCAA; Not Subject to Delisting*
Zai Lab Complies with the HFCAA; Not Subject to Delisting*
Read more →ZLAB▼ -5.3%on this news
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
Read more →ZLABZai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Read more →ZLABZai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
Read more →ZLAB▲ +6.7%on this news
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
Read more →ZLAB▼ -10.1%on this newsshared move
Zai Lab Complies with the HFCAA; Not Subject to Delisting
Zai Lab Complies with the HFCAA; Not Subject to Delisting
Read more →ZLAB▼ -10.1%on this newsshared move
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Read more →ZLABZai Lab to Announce Third Quarter 2024 Financial Results and Recent
Zai Lab Limited announced it will report its third quarter 2024 financial results on November 12, 2024. The company will host a conference call and webcast at 8:00 a.m. ET. Participants must register in advance to access the call. Zai Lab is focused on developing innovative products in various medical fields.
Read more →ZLABZai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
Read more →ZLABZai Lab Announces Participation in N
Zai Lab Limited has announced its participation in several upcoming investor conferences in November and December 2024. The events include the Goldman Sachs APAC Healthcare Corporate Day in Hong Kong, the Jefferies London Healthcare Conference, and Citi's Global Healthcare Conference in Miami. This engagement reflects Zai Lab's commitment to connecting with investors and showcasing its innovative biopharmaceutical efforts.
Read more →ZLABZai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Read more →ZLAB▼ -8.4%on this news
Zai Lab Announces Participation in Investor Conferences in March 2025
Zai Lab Announces Participation in Investor Conferences in March 2025
Read more →ZLABZai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
Zai Lab reported strong financial results for Q4 and full-year 2024, with total revenues growing 66% year-over-year to $109.1 million in Q4 and 50% to $399 million for the year. The company anticipates a revenue guidance of $560 million to $590 million for 2025, driven by the success of VYVGART and other pipeline assets. Early clinical data for ZL-1310 indicates promising potential in treating small cell lung cancer. However, the company continues to face substantial operating losses.
Read more →ZLABZai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates - Total revenues grew 66% y-o-y to $109.1 million for the fourth quarter of 2024 and 50% y-o-y to $399.0 million for the
Zai Lab reported robust financial results for Q4 and full-year 2024, showcasing a 66% year-on-year revenue growth in Q4 and 50% growth for the full year. The company's loss from operations significantly reduced, reflecting operational improvements. Notably, VYVGART and VYVGART Hytrulo contributed $93.6 million in sales in 2024, and Zai Lab anticipates a transformative year ahead in 2025 with new product launches and strong revenue guidance. Early clinical data from the ZL-1310 trial suggests promising potential for small cell lung cancer treatment.
Read more →ZLABZai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
Read more →ZLABZai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
Read more →ZLABZai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Read more →ZLABZai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Read more →ZLABZai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
Read more →ZLABZai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Read more →ZLABZai Lab Announces Participation in Investor Conference in January 2025
Zai Lab Announces Participation in Investor Conference in January 2025
Read more →ZLABZai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Read more →ZLABZai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Read more →ZLABZai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Read more →ZLABargenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Read more →ZLABZai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
Zai Lab Limited announced the anticipated closing of its public offering of 7,843,137 American depositary shares at $25.50 each. The underwriters exercised their option to purchase an additional 1,176,470 ADSs, bringing total proceeds to approximately $230 million. The closing is expected on November 19, 2024, pending customary conditions.
Read more →ZLAB▼ -7%on this newsshared move
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Read more →ZLAB▼ -11%on this newsshared move
Zai Lab Announces Pricing of Public Offering of American Depositary Shares SHANGHAI &
Zai Lab Limited announced the pricing of its public offering of 7,843,137 American depositary shares (ADSs) at $25.50 each, potentially raising $200 million. The shares are expected to be delivered by November 18, 2024, subject to customary conditions. This move allows Zai Lab to fund its general corporate purposes and reflects the company's proactive financing strategy. The offering is conducted under a previously effective shelf registration statement with the U.S. Securities and Exchange Commission.
Read more →ZLABZai Lab Announces Proposed Public Offering of American Depositary Shares
Zai Lab Announces Proposed Public Offering of American Depositary Shares
Read more →ZLABUpdated Risk Factors Risks Related to Our Business and Industry We, our employees, and our contracted third parties are subject to laws and government regulations relating to privacy and data protection that have require
ZLAB has updated its risk factors, highlighting significant challenges related to compliance with privacy and data protection laws. The company noted that evolving regulations may lead to increased expenses and affect their ability to process personal data. Additionally, there are concerns about maintaining essential licenses for product development and the potential impact of regulatory actions under anti-corruption laws in China and the U.S. These factors could materially affect ZLAB's operational capabilities and financial performance.
Read more →ZLAB▼ -6.9%on this newsshared move
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Zai Lab reported a strong financial performance for Q3 2024, with net product revenue increasing by 47% year-over-year to $101.8 million. The company announced positive results from a bridging study of KarXT for schizophrenia and highlighted the promising data from its global Phase 1 study of ZL-1310 for small cell lung cancer. Zai Lab also plans multiple product launches and regulatory submissions in the coming months, supported by a robust cash position.
Read more →ZLAB▼ -6.9%on this newsshared move
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates - Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 - Positive China bridging stud
Zai Lab reported strong financial results for Q3 2024, with net product revenues rising 47% year-over-year, reaching $101.8 million, bolstered by successful sales of VYVGART. The company also highlighted positive outcomes from a bridging study for KarXT in schizophrenia, expected to trigger a regulatory submission in early 2025. Additionally, Zai Lab's pipeline data for ZL-1310 in small cell lung cancer suggest promising therapeutic potential. However, the company reported a net loss of $41.7 million for the quarter, showing ongoing challenges despite positive revenue growth.
Read more →ZLABZai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Read more →ZLABBristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Read more →ZLABZai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
Read more →ZLAB▲ +14.7%on this newsshared move
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
Read more →ZLABZai Lab Announces Participation in November and December Investor Conferences
Zai Lab Announces Participation in November and December Investor Conferences
Read more →ZLABZai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
Read more →ZLAB▲ +5.6%on this newsshared move
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
Read more →ZLABFDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Read more →ZLABZai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
Read more →ZLAB▲ +11.1%on this news· ran to +22% by day 3
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Read more →ZLAB▼ -5.2%on this newsshared move
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
Zai Lab reported a net product revenue of $100.1 million for Q2 2024, marking a 45% year-over-year growth. The company raised its revenue guidance for VYVGART to exceed $80 million, driven by its successful launch and positive market reception. Zai Lab also expanded its oncology pipeline with a new ADC program and achieved three product approvals in China. Despite a net loss of $80.3 million, the company maintains a strong cash position of $730 million.
Read more →ZLAB▼ -5.2%on this newsshared move
啊人跟新AnnouncesFDAApproval哦分VYVGARTH要投入咯forChronicInflammatoryDemyelinatingPoly’neu’ro’path
argenx SE announced FDA approval for VYVGART Hytrulo, the first treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in over 30 years. This once-weekly subcutaneous injection has shown significant clinical benefits in patients, with 69% demonstrating improvement in mobility and function. The approval is based on the ADHERE study, which highlighted the treatment's potential in addressing CIDP effectively.
Read more →ZLABZai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
Read more →ZLABZai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Read more →ZLABZai Lab Announces Participation in September Investor Conferences
Zai Lab Announces Participation in September Investor Conferences
Read more →ZLABZai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates - Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth 47% y-o-y growth at constant exch
Zai Lab reported strong financial results for Q2 2024, with net product revenues of $100.1 million, reflecting a 45% year-over-year increase. VYVGART achieved notable sales of $23.2 million, prompting the company to raise its annual revenue guidance for the product. The firm is expanding its oncology pipeline, introducing a next-generation ROR1 antibody-drug conjugate program. However, they also faced a net loss of $80.3 million and increased administrative costs during the period, despite overall growth.
Read more →ZLABParatek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Read more →ZLABZai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Read more →ZLABZai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Read more →ZLABZai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Read more →ZLABargenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath
Read more →ZLABU.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Read more →ZLABZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Zai Lab announced the retirement of Dr. Harald Reinhart, who has led Global Development for nearly a decade. Dr. Rafael Amado will take over as President and Head of Global R&D, expanding his responsibilities. The transition aims to maintain the company's growth trajectory in neuroscience, autoimmune, and infectious diseases.
Read more →ZLABZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Read more →ZLABMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
Read more →ZLABZai Lab Announces Participation in January Investor Conference
Zai Lab Limited announced its participation in the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024. The presentation will be made by senior management and will be available via live webcast. This event highlights Zai Lab's commitment to innovation in biopharmaceuticals and its focus on addressing unmet medical needs.
Read more →ZLABZai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
Zai Lab Limited announced that VYVGART (efgartigimod alfa injection) has been included in China's National Reimbursement Drug List (NRDL) for treating generalized myasthenia gravis (gMG). This marks a significant milestone for patients with gMG, enhancing their access to critical treatment. Additionally, NUZYRA and ZEJULA have also been included or renewed in the NRDL, further improving patient access to essential medications.
Read more →ZLABKaruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Karuna Therapeutics announced that the FDA has accepted its New Drug Application for KarXT, an investigational treatment for schizophrenia. The PDUFA date is set for September 26, 2024. The application is backed by positive results from the EMERGENT clinical trial program, indicating significant symptom improvements. If approved, KarXT could revolutionize treatment options in neuropsychiatry.
Read more →ZLABU.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
The FDA has approved Augtyro (repotrectinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This approval is based on the TRIDENT-1 trial, which showed a 79% objective response rate in TKI-naïve patients. Augtyro is an oral tyrosine kinase inhibitor that targets ROS1 oncogenic fusions and is expected to be available in the U.S. by mid-December 2023.
Read more →ZLABZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics have received NMPA approval for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii in China. This approval follows positive results from the ATTACK trial, showing XACDURO's efficacy against carbapenem-resistant infections. The drug is seen as a significant advancement in combating drug-resistant bacterial infections.
Read more →ZLABZai Lab Announces Participation in May and June Investor Conferences
Zai Lab Limited has announced its participation in several upcoming investor conferences in May and June 2024. The events include the J.P. Morgan 20th Annual Global China Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs 45th Annual Global Healthcare Conference. These engagements aim to enhance the company's visibility and connect with potential investors.
Read more →ZLABZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zai Lab has announced the acceptance of its supplemental Biologics License Application for efgartigimod alfa injection for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in China. The application is based on positive results from the ADHERE trial, which showed significant efficacy in reducing relapse rates. This milestone highlights Zai Lab's commitment to addressing unmet medical needs in China.
Read more →ZLABZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
Zai Lab announced that the National Medical Products Administration (NMPA) in China has approved AUGTYRO (repotrectinib) for treating adult patients with ROS1-positive non-small-cell lung cancer (NSCLC). This approval is based on the pivotal TRIDENT-1 trial, which demonstrated high response rates and durable responses. The drug aims to address the unmet medical needs of patients with limited treatment options.
Read more →ZLABZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
Zai Lab reported a net product revenue of $87.1 million for Q1 2024, marking a 39% increase year-over-year. The successful launch of VYVGART contributed to this growth, generating $13.2 million in sales. Despite a net loss of $53.5 million, the company maintains a strong cash position and anticipates further growth with upcoming product launches. Regulatory reviews for several products are ongoing.
Read more →ZLABFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
The FDA has granted full approval for TIVDAK (tisotumab vedotin-tftv) to treat recurrent or metastatic cervical cancer, based on positive results from the Phase 3 innovaTV 301 trial. This approval marks TIVDAK as the first antibody-drug conjugate to demonstrate significant overall survival benefits compared to chemotherapy. The treatment is crucial for patients with limited options, although it carries risks of ocular toxicity and other adverse reactions.
Read more →ZLABResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure announced that the results of the METIS Phase 3 clinical trial will be presented at ASCO 2024. The trial demonstrated that Tumor Treating Fields therapy significantly improved time to intracranial progression in patients with brain metastases from non-small cell lung cancer. The findings are expected to contribute to future regulatory discussions.
Read more →ZLABargenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Argenx SE presented promising data from its Phase 3 ADHERE trial for VYVGART Hytrulo at the AAN Annual Meeting. The trial showed significant clinical improvements in CIDP patients, including a 61% reduction in relapse risk. Additionally, real-world data indicated that gMG patients could reduce steroid use significantly. The FDA is expected to make a decision on the supplemental Biologics License Application by June 21, 2024.
Read more →ZLABZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Zai Lab Limited will report its first quarter 2024 financial results on May 8, 2024, after market close. A conference call and webcast will follow on May 9, 2024, at 8:00 a.m. ET. Participants must register in advance to access the call, which will also be available for replay on the company's website.
Read more →ZLABZai Lab Statement on Executive Management Team’s Agreement on Share Activities
Zai Lab's Executive Officers have announced their agreement not to sell shares for the remainder of 2024, except for specific pre-existing plans or tax obligations. This decision reflects their confidence in the company's future and commitment to its growth. Zai Lab is focused on developing innovative treatments for various medical conditions.
Read more →ZLABKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Bristol Myers Squibb announced promising results from the Phase 1/2 KRYSTAL-1 study, showcasing KRAZATI (adagrasib) combined with cetuximab for KRASG12C-mutated colorectal cancer. The treatment achieved a 34% objective response rate and a median overall survival of 15.9 months in previously treated patients. The findings will be presented at the AACR annual meeting and have implications for future treatment options.
Read more →ZLABBristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Bristol Myers Squibb presented interim data from the Phase 3 EMERGENT program for KarXT in schizophrenia at the 2024 SIRS Congress. The data indicated that 65% of patients experienced weight reductions, and the treatment was generally well tolerated over 52 weeks. No significant adverse effects related to prolactin or movement disorders were observed, highlighting KarXT's potential as a differentiated treatment option.
Read more →ZLABBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Bristol Myers Squibb presented new interim results from the Phase 3 EMERGENT-4 trial, showing that KarXT significantly improves schizophrenia symptoms over 52 weeks. More than 75% of participants achieved over 30% symptom improvement. The trial indicates KarXT's potential as a long-term treatment option, with favorable safety and tolerability profiles.
Read more →ZLABZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Zai Lab Limited will present ongoing clinical studies at the AACR 2024 Annual Meeting, highlighting its Phase 1 trials for ZL-1310 and ZL-1218. ZL-1310 is an antibody-drug conjugate targeting DLL3 for small cell lung cancer, while ZL-1218 is an anti-CCR8 antibody aimed at advanced solid tumors. These presentations reflect Zai Lab's commitment to oncology innovation.
Read more →ZLABZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Zai Lab's partner, Bristol Myers Squibb, announced that the Phase 3 KRYSTAL-12 trial of KRAZATI (adagrasib) for KRAS G12C-mutated non-small cell lung cancer met its primary endpoint of progression-free survival. The study also showed a significant overall response rate compared to standard chemotherapy. Zai Lab intends to submit a New Drug Application for KRAZATI in China this year.
Read more →ZLABargenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
argenx SE announced the advancement of efgartigimod to Phase 3 for adults with primary Sjogren's disease, based on favorable results from the Phase 2 RHO study. The decision is supported by a positive safety profile and efficacy data across multiple endpoints. Detailed results are expected to be presented at an upcoming medical meeting.
Read more →ZLABZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
The METIS Phase 3 clinical trial, conducted by Novocure, has successfully met its primary endpoint, showing a significant improvement in the median time to intracranial progression for patients with brain metastases from non-small cell lung cancer when treated with Tumor Treating Fields (TTFields) therapy. Patients receiving TTFields therapy exhibited a median progression time of 21.9 months compared to 11.3 months for those receiving supportive care alone. While the trial demonstrated positive results, some secondary endpoints did not reach statistical significance, and further analysis is ongoing.
Read more →ZLABargenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
argenx SE announced that Japan's Ministry of Health has approved VYVGART (efgartigimod alfa) for adults with primary immune thrombocytopenia (ITP). This marks the first global approval for VYVGART in ITP, following successful results from the Phase 3 ADVANCE-IV trial. The treatment demonstrated a significant response rate and was well-tolerated among patients. This approval represents a significant advancement for patients in Japan seeking new treatment options for ITP.
Read more →ZLABZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
Zai Lab announced the presentation of preclinical data for ZL-1310, an innovative antibody-drug conjugate targeting DLL3, at the European Lung Cancer Congress 2024. The data indicates ZL-1310's potential in treating small cell lung cancer and other DLL3+ solid tumors. The findings support the initiation of a Phase 1 clinical trial for relapsed and refractory SCLC patients.
Read more →ZLABZai Lab Announces Participation in March Investor Conference
Zai Lab Limited announced its participation in the Leerink Partners Global Biopharma Conference on March 11, 2024. Senior management will present at the event, which will be available via live webcast. The company focuses on innovative biopharmaceutical solutions for various medical conditions, emphasizing its commitment to improving global health.
Read more →ZLABZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
Zai Lab announced that final overall survival data from the Phase 3 NORA study of ZEJULA (niraparib) will be presented at the 2024 ESGO and SGO conferences. The study evaluated niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer. Previous data indicated benefits of individualized dosing, and no new safety signals were reported during follow-up.
Read more →ZLABZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
Zai Lab reported a total product revenue of $266.7 million for 2023, marking a 25% year-over-year increase. The launch of VYVGART in China has been successful, with nearly 1,000 patients treated and expectations for significant sales growth in 2024. The company maintains a strong cash position but reported a net loss, highlighting challenges in the market.
Read more →ZLABargenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
argenx announced that the FDA has accepted its supplemental Biologics License Application for VYVGART Hytrulo, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), with a PDUFA target action date of June 21, 2024. This application is supported by data from the ADHERE study, which demonstrated a significant reduction in relapse rates among treated patients. If approved, VYVGART Hytrulo will be the first FcRn blocker for CIDP, addressing a critical need for new treatment options in this area.
Read more →ZLABU.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or…
The FDA has accepted Bristol Myers Squibb's supplemental new drug application for KRAZATI (adagrasib) in combination with cetuximab for treating previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer. The application is based on data from the Phase 1/2 KRYSTAL-1 study, which indicated promising clinical activity and manageable safety profiles. The target action date for the FDA's decision is set for June 21, 2024.
Read more →ZLABU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Bristol Myers Squibb announced that the FDA has accepted its application for Augtyro (repotrectinib) for treating NTRK-positive locally advanced or metastatic solid tumors. This application is based on promising results from the TRIDENT-1 and CARE trials. The FDA has assigned a target action date of June 15, 2024, for its decision.
Read more →ZLABZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
Zai Lab Limited will announce its full-year 2023 financial results on February 27, 2024, after market close. A conference call and webcast will follow on February 28, 2024, at 8:00 a.m. ET. The company aims to provide updates on its corporate activities and financial performance.
Read more →ZLABNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Novocure announced that the FDA has accepted its PMA application for Tumor Treating Fields therapy in treating non-small cell lung cancer (NSCLC) after platinum-based therapy. The application is based on the LUNAR trial data, which demonstrated improved survival rates for patients receiving TTFields therapy. A regulatory decision is expected in the second half of 2024.
Read more →ZLABargenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
argenx SE announced that Japan's Ministry of Health has approved VYVDURA for subcutaneous use in treating generalized myasthenia gravis (gMG) in adults. This approval allows patients who do not respond adequately to steroids or other immunosuppressive therapies to access this new treatment option. VYVDURA's efficacy was demonstrated in the Phase 3 ADAPT-SC study, showing comparable results to the intravenous formulation, VYVGART.
Read more →ZLABZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Zai Lab announced the publication of Phase 1/2 TRIDENT-1 study data in NEJM, showcasing repotrectinib's effectiveness in treating ROS1 fusion-positive non-small cell lung cancer (NSCLC). The drug demonstrated high response rates and durable activity in both treatment-naïve and pretreated patients. The study indicates potential advantages over first-generation TKIs, particularly in addressing resistance mutations.
Read more →ZLABZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Read more →ZLABZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates - Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth 43% y-o-y growth at constant exchang
Zai Lab Limited announced its financial results for the first quarter of 2024, reporting a net product revenue of $87.1 million, marking a 39% year-on-year increase. The impressive performance was driven by the successful launch of VYVGART, which generated sales of $13.2 million in its inaugural quarter. Despite the growth in revenues, the company reported a net loss of $53.5 million, reflecting increased operational costs. The firm remains optimistic about its future growth trajectory, bolstered by a strong cash position and ongoing regulatory reviews for multiple product candidates.
Read more →ZLABargenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease – Zai Lab Limited
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease – Zai Lab Limited
Read more →ZLABZai Lab Statement on Executive Management Team’s Agreement on Share Activities – Zai Lab Limited
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities – Zai Lab Limited
Read more →ZLABBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society – Zai Lab Limited
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society – Zai Lab Limited
Read more →ZLABargenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease – Zai Lab Limited
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease – Zai Lab Limited
Read more →ZLABZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer – Zai Lab Limited
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer – Zai Lab Limited
Read more →ZLABargenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited
Read more →ZLABZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) – Zai Lab Limited
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) – Zai Lab Limited
Read more →ZLAB▲ +7.1%on this news
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates - Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth 31% y-o-y growth at constant exchange rate (CER)
Zai Lab reported its financial results for the full year of 2023, achieving a 25% increase in product revenue to $266.7 million. The launch of VYVGART in September 2023 was particularly highlighted, with expectations of significant sales following its inclusion in China's National Reimbursement Drug List. Despite the positive revenue growth, the company posted a net loss of $334.6 million, albeit lower than the previous year's loss. The financial outlook for 2024 includes focused efforts on expanding product availability and sustaining growth through new launches and market penetration.
Read more →ZLABZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024 – Zai Lab Limited
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024 – Zai Lab Limited
Read more →ZLABargenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis – Zai Lab Limited
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis – Zai Lab Limited
Read more →ZLABZai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List – Zai Lab Limited
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List – Zai Lab Limited
Read more →ZLAB▲ +6%on this news
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Zai Lab reported a total product revenue of $69.2 million for Q3 2023, marking a 22% year-over-year increase. The company launched VYVGART in China and reported positive trial results for efgartigimod in CIDP. Despite a strong cash position of $822.2 million, Zai Lab experienced a net loss of $69.2 million, influenced by recent regulatory challenges in China.
Read more →ZLABTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
The Phase 3 innovaTV 301 trial results reveal that TIVDAK (tisotumab vedotin-tftv) significantly improves overall survival and progression-free survival in patients with recurrent or metastatic cervical cancer compared to chemotherapy. The trial demonstrated a 30% reduction in the risk of death and a 33% reduction in disease progression. These findings support TIVDAK's potential as a new treatment option for patients with limited alternatives.
Read more →ZLABZai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates - Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth 27% y-o-y growth at constant excha
Zai Lab Limited announced its financial results for Q3 2023, reporting product revenues of $69.2 million, a 22% year-over-year increase. The launch of VYVGART in China contributed $4.9 million in sales, signaling strong market entry. Despite a significant cash position of $822.2 million, the company reported a net loss of $69.2 million, improved from the previous year's loss. Challenges such as industry-wide anti-corruption enforcement have affected revenue growth, although future pipeline prospects remain strong with several drug approvals and launches anticipated.
Read more →ZLABTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial – Zai Lab Limited
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial – Zai Lab Limited
Read more →ZLABZai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
Zai Lab Limited will report its third quarter 2023 financial results on November 7, 2023, after market close. A conference call and webcast will follow on November 8, 2023, at 8:00 a.m. ET. The event will provide insights into the company's recent corporate updates and financial performance.
Read more →ZLABCullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Cullinan Oncology announced positive interim data from its Phase 1/2a trial of CLN-081, an EGFR inhibitor for NSCLC patients with exon 20 mutations. The trial showed a confirmed objective response rate of 46% at the 100 mg BID dose, with an acceptable safety profile. The company has initiated a Phase 2a expansion cohort to further evaluate the drug's efficacy.
Read more →ZLABRegeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials
Regeneron has announced the resumption of patient enrollment in its odronextamab trials for follicular lymphoma and diffuse large B-cell lymphoma after the FDA lifted a partial clinical hold. The trial protocols have been updated to minimize the risk of severe cytokine release syndrome during dosing. Enrollment will begin immediately for the affected patient cohorts.
Read more →ZLABSEC Declares That There Are Currently No Issuers at Risk of Delisting Due to the Holding Foreign Companies Accountable Act
Zai Lab has confirmed that its Nasdaq listing is secure and will not be affected by the Holding Foreign Companies Accountable Act (HFCAA). The SEC has stated that there are currently no issuers at risk of delisting due to the HFCAA, following the PCAOB's recent vacating of its previous determinations. Zai Lab continues to be audited by KPMG LLP.
Read more →ZLABKaruna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
Karuna Therapeutics has submitted a New Drug Application (NDA) for KarXT, a novel treatment for schizophrenia, to the FDA. This submission is supported by data from three successful clinical trials demonstrating significant symptom reduction. If approved, KarXT could offer a new therapeutic option with a different mechanism of action compared to existing treatments.
Read more →ZLABZai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
Zai Lab has received Breakthrough Therapy Designation from the NMPA for efgartigimod alfa injection (subcutaneous) to treat chronic inflammatory demyelinating polyneuropathy (CIDP). This designation is based on promising data from the ADHERE study, which showed significant efficacy and a favorable safety profile. The company aims to expedite the availability of this innovative treatment for patients in China.
Read more →ZLABargenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
argenx has received a positive opinion from the CHMP for its subcutaneous formulation of efgartigimod for treating generalized myasthenia gravis (gMG). This recommendation is based on the Phase 3 ADAPT-SC study, which showed that the subcutaneous administration is noninferior to intravenous delivery in reducing total IgG levels. A decision from the European Commission on marketing authorization is expected within 60 days.
Read more →ZLABargenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis – Zai Lab Limited
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis – Zai Lab Limited
Read more →ZLABSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
Seagen and Genmab announced that their Phase 3 trial of TIVDAK (tisotumab vedotin-tftv) for recurrent or metastatic cervical cancer met its primary endpoint of improved overall survival compared to chemotherapy alone. The trial also showed statistical significance in secondary endpoints, with no new safety concerns reported. The results will support regulatory applications and discussions.
Read more →ZLAB▲ +11.4%on this newsshared move
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China – Zai Lab Limited
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China – Zai Lab Limited
Read more →ZLABUpdated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Updated data from the TRIDENT-1 trial show that repotrectinib exhibits high response rates and durable efficacy in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The results, presented at the IASLC 2023 World Conference on Lung Cancer, indicate significant intracranial responses and support the drug's potential as a new standard of care. The FDA has accepted a New Drug Application for repotrectinib with a Priority Review designation.
Read more →ZLABUpdated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer – Zai Lab Limited
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer – Zai Lab Limited
Read more →ZLAB▼ -6.2%on this news
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
Zai Lab reported a 45% increase in product revenue for Q2 2023, reaching $68.9 million. The company achieved a significant milestone with the approval of VYVGART as the first neonatal Fc receptor blocker for generalized myasthenia gravis in China. Despite a net loss of $120.9 million, Zai Lab maintains a strong cash position, supporting its growth strategy and pipeline advancements.
Read more →ZLABZai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates - Total product revenue of $68.9 million for the second quarter of 2023, representing 45% y-o-y growth 53% y-o-y growth at constant exchange r
Zai Lab Limited reported its second quarter 2023 financial results, showcasing notable growth with product revenues reaching $68.9 million, a 45% increase year-over-year. Significant milestones include the approval of VYVGART in China for generalized myasthenia gravis and positive results from the ADHERE trial regarding chronic inflammatory demyelinating polyneuropathy. Despite a decrease in cash position, the company maintains robust projections for revenue growth and plans to launch multiple commercial-stage products by 2028.
Read more →ZLABZai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
Zai Lab Limited will announce its financial results for the second quarter of 2023 on August 7, 2023. Following this, the company will host a conference call and webcast on August 8, 2023, at 8:00 a.m. ET. This event aims to update stakeholders on the company's performance and recent developments.
Read more →ZLABJAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
The Phase 3 PRIME study published in JAMA Oncology shows that ZEJULA (niraparib) significantly prolongs progression-free survival in patients with advanced ovarian cancer. The study found a 55% reduction in the risk of disease progression or death compared to placebo. These results affirm ZEJULA's effectiveness as a first-line maintenance therapy, regardless of biomarker status.
Read more →ZLAB▼ -6.6%on this newsshared move
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Zai Lab and argenx announced positive topline results from the ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint, showing a 61% reduction in relapse risk compared to placebo. A significant number of patients demonstrated clinical improvement, indicating the potential of VYVGART Hytrulo as an effective treatment option for CIDP. The safety profile was favorable and consistent with previous studies.
Read more →ZLABZai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
Zai Lab has announced the treatment of the first patient in mainland China for the Phase 3 FORTITUDE-101 study of bemarituzumab, aimed at treating first-line gastric cancer. This global trial focuses on patients with FGFR2b overexpression, a significant target as there are currently no approved treatments for this condition. The study is sponsored by Amgen and represents a crucial step in expanding treatment options for advanced gastric cancer.
Read more →ZLABZai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
Zai Lab has announced that China's NMPA has accepted the Biologics License Application for efgartigimod alfa injection, aimed at treating adult patients with generalized myasthenia gravis. The acceptance is backed by positive Phase 3 study results showing effective IgG reduction. The drug offers flexible administration options, enhancing treatment accessibility for patients.
Read more →ZLABZai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China – Zai Lab Limited
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China – Zai Lab Limited
Read more →ZLAB▼ -6.9%on this news
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis – Zai Lab Limited
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis – Zai Lab Limited
Read more →ZLABZai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting – Zai Lab Limited
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting – Zai Lab Limited
Read more →ZLABZai Lab Announces First Quarter 2023 Financial Results and Corporate Updates - Total product revenue of $62.8 million for the first quarter of 2023, representing a 36% increase y-o-y ZEJULA achieved 44% y-o-y growth - Ex
Zai Lab Limited has announced its financial results for the first quarter of 2023, reporting a 36% increase in total product revenue to $62.8 million. The company highlighted strong performance from ZEJULA, which saw a 44% growth year-over-year. Notably, Zai Lab is expanding its pipeline with new clinical programs and receiving positive data from recent studies, positioning itself well in the oncology market. However, the company faces challenges related to its reduced cash position and the overall market dynamics following China's reopening.
Read more →ZLABJournal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors – Zai Lab Limited
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors – Zai Lab Limited
Read more →ZLABZai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – Zai Lab Limited
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – Zai Lab Limited
Read more →ZLAB▲ +8.7%on this news
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates - Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y ZEJULA achieved 55.2% y-o-y growth - Strong balance sheet wi
Zai Lab reported its financial results for 2022, noting a substantial revenue increase of 49% to $215 million. The company's pipeline shows promising late-stage developments, with several assets gaining positive results. Zai Lab aims to achieve commercial profitability in 2023 and plans to launch at least 8 new products by the end of 2025. The company has a strong cash position of $1 billion to support its growth initiatives in the biopharmaceutical sector.
Read more →ZLABZai Lab Announces Participation in March Investor Conferences – Zai Lab Limited
Zai Lab Announces Participation in March Investor Conferences – Zai Lab Limited
Read more →ZLABZai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress – Zai Lab Limited
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress – Zai Lab Limited
Read more →ZLABZai Lab Announces Participation in February Investor Conferences – Zai Lab Limited
Zai Lab Announces Participation in February Investor Conferences – Zai Lab Limited
Read more →ZLABZai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA – Zai Lab Limited
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA – Zai Lab Limited
Read more →ZLAB▼ -9%on this news
Zai Lab Appoints Michel Vounatsos To Its Board of Directors SHANGHAI and
Zai Lab has appointed Michel Vounatsos to its Board of Directors, effective January 7, 2023. Vounatsos brings extensive global experience in the biopharmaceutical industry, particularly in China and neuroscience. His appointment is expected to strengthen Zai Lab's strategic direction and commercialization efforts as the company works on expanding its product offerings. Zai Lab currently has four medicines on the market and plans to launch three more soon.
Read more →ZLAB▲ +41.8%on this newsshared move
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Read more →ZLABMirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer – Zai Lab Limited
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer – Zai Lab Limited
Read more →ZLABZai Lab Announces Participation in January Investor Conferences – Zai Lab Limited
Zai Lab Announces Participation in January Investor Conferences – Zai Lab Limited
Read more →ZLABMirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation – Zai Lab Limited
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation – Zai Lab Limited
Read more →ZLAB▼ -7.8%on this news
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) – Zai Lab Limited
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) – Zai Lab Limited
Read more →ZLABargenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review – Zai Lab Limited
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review – Zai Lab Limited
Read more →ZLAB▲ +6.4%on this news· ran to +35% by day 3
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates - Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q continued revenue growth l
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates -Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q continued revenue growth led by ZEJULA -Regional strategic collaboration for TIVDAK
Read more →ZLAB▼ -6.9%on this news· ran to +18% by day 3shared move
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer – Zai Lab Limited
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer – Zai Lab Limited
Read more →ZLABZai Lab Launches its first Trust Report – Zai Lab Limited
Zai Lab Launches its first Trust Report – Zai Lab Limited
Read more →ZLAB▼ -7.8%on this news
Zai Lab Believes its Engagement of KPMG LLP is Consistent with PCAOB Requirements and Complies with the HFCAA – Zai Lab Limited
Zai Lab Believes its Engagement of KPMG LLP is Consistent with PCAOB Requirements and Complies with the HFCAA – Zai Lab Limited
Read more →ZLABSeagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK (tisotumab vedotin-tftv) -- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Cla
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK (tisotumab vedotin-tftv) -- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong K
Read more →ZLAB▲ +5.6%on this news· ran to -20% by day 3
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting – Zai Lab Limited
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting – Zai Lab Limited
Read more →ZLABZai Lab’s Statement Regarding U.S./China Agreement Concerning PCAOB Inspection and Review of Auditors – Zai Lab Limited
Zai Lab’s Statement Regarding U.S./China Agreement Concerning PCAOB Inspection and Review of Auditors – Zai Lab Limited
Read more →ZLABZai Lab Announces Participation in September Investor Conferences – Zai Lab Limited
Zai Lab Announces Participation in September Investor Conferences – Zai Lab Limited
Read more →ZLABargenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis News August 11, 2022 – Zai Lab Limited
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis News August 11, 2022 – Zai Lab Limited
Read more →ZLABZai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates - Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China's NMPA and positive topline results for the KarXT Pha
Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates -Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China's NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial -Continued revenue growth led by ZEJ
Read more →ZLABZai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis – Zai Lab Limited
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis – Zai Lab Limited
Read more →ZLABZai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited – Zai Lab Limited
Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited – Zai Lab Limited
Read more →ZLABZai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China – Zai Lab Limited
Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China – Zai Lab Limited
Read more →ZLABZai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference – Zai Lab Limited
Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference – Zai Lab Limited
Read more →ZLABHong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly d
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever ari
Read more →ZLABZai Lab Announces First Quarter 2022 Financial Results and Corporate Updates Company to Host Conference Call and Webcast on
Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., May 10, 2022 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused,
Read more →ZLAB▼ -6.6%on this news
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study – Zai Lab Limited
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study – Zai Lab Limited
Read more →ZLAB▼ -6.2%on this news
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm – Zai Lab Limited
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm – Zai Lab Limited
Read more →ZLABZai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022 – Zai Lab Limited
Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022 – Zai Lab Limited
Read more →ZLAB▲ +5.4%on this newsshared move
Zai Lab Plants a Tree for Every Employee on Earth Day 2022 – Zai Lab Limited
Zai Lab Plants a Tree for Every Employee on Earth Day 2022 – Zai Lab Limited
Read more →ZLAB▲ +5.2%on this newsshared move
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study – Zai Lab Limited
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study – Zai Lab Limited
Read more →ZLABZai Lab to Present New Oncology Research at 2022 AACR Annual Meeting – Zai Lab Limited
Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting – Zai Lab Limited
Read more →ZLABZai Lab Statement on SEC Listing Matter – Zai Lab Limited
Zai Lab Statement on SEC Listing Matter – Zai Lab Limited
Read more →ZLAB▲ +11%on this news
argenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis – Zai Lab Limited
argenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis – Zai Lab Limited
Read more →ZLABZai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer SHANGHAI, SAN FRANCISCO, and
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass. March 15, 2022 (EDT) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today an
Read more →ZLABZai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021 Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. EST SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., March 1, 2022 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9
Read more →ZLABZai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
Read more →ZLAB▲ +8.5%on this newsshared move
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer – Zai Lab Limited
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer – Zai Lab Limited
Read more →ZLABargenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis – Zai Lab Limited
argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis – Zai Lab Limited
Read more →ZLABZai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA SHANGHAI, SAN FRANCISCO, and
Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., January 6, 2022 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-s
Read more →ZLAB▼ -7.5%on this newsshared move
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer – Zai Lab Limited
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer – Zai Lab Limited
Read more →ZLABZai Lab announces promotion of Harald Reinhart M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases SHANGHAI, SAN FRANCISCO, and
Zai Lab announces promotion of Harald Reinhart M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient
Read more →ZLAB▲ +10.6%on this newsshared move
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis – Zai Lab Limited
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis – Zai Lab Limited
Read more →ZLAB▲ +20.7%on this news· ran to +34% by day 1shared move
China NMPA Approves NUZYRA as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) NUZYRA demonstra
China NMPA Approves NUZYRA as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections demonstrated efficacy against common pathogens in three Phase 3 studies, includi
Read more →ZLAB▼ -8.5%on this news
Zai Lab Announces Inclusion of ZEJULA (Niraparib) in China s National Reimbursement Drug List for First-Line Ovarian Cancer SHANGHAI, SAN FRANCISCO, and
Zai Lab Announces Inclusion of ZEJULA (Niraparib) in China s National Reimbursement Drug List for First-Line Ovarian Cancer SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., December 3, 2021 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-sta
Read more →ZLAB▼ -12.5%on this news
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer – Zai Lab Limited
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer – Zai Lab Limited
Read more →ZLAB▼ -12.5%on this news
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors SHANGHAI, SAN FRANCISCO, and
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., November 22, 2021 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that it
Read more →ZLAB▲ +5.9%on this news
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Read more →ZLABZai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus
Read more →ZLABZai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia
Read more →ZLABZai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates
Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates
Read more →ZLABZai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Read more →ZLABZai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China -- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Grea
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China -- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in -- Collaboration accelerates and expands global development o
Read more →ZLABZai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab
Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab
Read more →ZLABZL-1102, Zai Lab s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema
ZL-1102, Zai Lab s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in
Read more →ZLABZai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carba
Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistic
Read more →ZLABZai Lab Appoints Scott Morrison to its Board of Directors SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, MA
Zai Lab Appoints Scott Morrison to its Board of Directors FRANCISCO, and CAMBRIDGE, MA, October 18, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has
Read more →ZLABZai Lab Announces Upcoming Presentations in October Investor Conferences
Zai Lab Announces Upcoming Presentations in October Investor Conferences
Read more →ZLABZai Lab Holds Virtual Research and Development Day
Zai Lab Holds Virtual Research and Development Day
Read more →ZLABZai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community
Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community
Read more →ZLABNovocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
Read more →ZLAB▼ -8.4%on this newsshared move
Zai Lab to Host Virtual Research and Development Day on September 22, 2021
Zai Lab to Host Virtual Research and Development Day on September 22, 2021
Read more →ZLABQINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Read more →ZLABZai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates Company to Host Conference Call and Webcast on
Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT SHANGHAI and SAN FRANCISCO, August 9, 2021 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage
Read more →ZLABZai Lab to Announce Second Quarter 2021 Financial Results
Zai Lab to Announce Second Quarter 2021 Financial Results
Read more →ZLABNovocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Read more →ZLABMirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
Read more →ZLABargenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Read more →ZLABZai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology Zai Lab granted combination of regional Asian and global rights for up to four C
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology SHANGHAI and SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative c
Read more →ZLABParatek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Read more →ZLABMirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China SAN DIEGO, SHANGHAI and SAN FRANCISCO June 1, 2021 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASD
Read more →ZLABRegeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials
Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials
Read more →ZLABNovocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Read more →ZLABZai Lab Reports First Quarter 2021 Financial Results Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT SHANGHAI and
Zai Lab Reports First Quarter 2021 Financial Results Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT SHANGHAI and SAN FRANCISCO, May 10, 2021 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announce
Read more →ZLABZai Lab to Announce First Quarter 2021 Financial Results on May 10, 2021
Zai Lab to Announce First Quarter 2021 Financial Results on May 10, 2021
Read more →ZLABZai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
Read more →ZLABZai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
Read more →ZLABAmgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
Read more →ZLABZai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnec
Read more →ZLABTurning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
Read more →ZLABChina NMPA Approves QINLOCK (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST QINLOCK dem
China NMPA Approves QINLOCK (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST QINLOCK demonstrated a significant improvement in progression-free survival and a clini
Read more →ZLABargenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
Read more →ZLABZai Lab Announces Financial Results for Second-half and Full-year 2020 Company to Host Conference Call and Webcast Today at 8:00 a.m. ET SHANGHAI and
Zai Lab Announces Financial Results for Second-half and Full-year 2020 Company to Host Conference Call and Webcast Today at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO, March 1, 2021 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical compa
Read more →ZLABargenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
Read more →ZLABTurning Point and Zai Lab Broaden Collaboration
Turning Point and Zai Lab Broaden Collaboration
Read more →ZLABTURNING POINT AND ZAI LAB BROADEN COLLABORATION Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfron
TURNING POINT AND ZAI LAB BROADEN COLLABORATION Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately $336 Million in Potential Mi
Read more →ZLABargenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potent
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China Regulated Information/Inside Information Breda, the Netherlands, Shanghai and San Francisco Jan. 6, 2021 argenx SE (Euronext & NASDAQ: ARGX), a global immunology company committed to improvin
Read more →ZLABZai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
Read more →ZLABZai Lab Announces Inclusion of ZEJULA (Niraparib) in China s National Reimbursement Drug List SHANGHAI and
Zai Lab Announces Inclusion of ZEJULA (Niraparib) in China s National Reimbursement Drug List SHANGHAI and SAN FRANCISCO, December 29, 2020 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has bee
Read more →ZLABZai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China - Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $2
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China - Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestone
Read more →ZLABZai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology SHANGHAI and
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology SHANGHAI and SAN FRANCISCO, Dec. 1, 2020 - Zai Lab Limited ( Zai Lab ) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment o
Read more →ZLABZai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer – Zai Lab Limited
Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer – Zai Lab Limited
Read more →ZLABHong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any l
Read more →ZLABHong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange ) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announce
(Incorporated in the Cayman Islands with limited liability) FULL EXERCISE OF THE OVER-ALLOTMENT OPTION We refer to the Prospectus, the allotment results announcement of the Company dated September 25, 2020 and the clarification announcement of the Company dated September 25, 20
Read more →ZLABZai Lab Announces Closing of Hong Kong Secondary Listing SHANGHAI and
Zai Lab Announces Closing of Hong Kong Secondary Listing SHANGHAI and SAN FRANCISCO, September 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited ( Zai Lab or the Company ) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary s
Read more →ZLABZai Lab Announces Pricing of Hong Kong Secondary Listing SHANGHAI and
Zai Lab Announces Pricing of Hong Kong Secondary Listing SHANGHAI and SAN FRANCISCO, September 22, 2020 (GLOBE NEWSWIRE) Zai Lab Limited ( Zai Lab or the Company ) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong K
Read more →ZLABPhase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer
Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer
Read more →ZLABZai Lab Launches Hong Kong Secondary Listing SHANGHAI and
Zai Lab Launches Hong Kong Secondary Listing SHANGHAI and SAN FRANCISCO, September 16, 2020 (GLOBE NEWSWIRE) Zai Lab Limited ( Zai Lab or the Company ) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public off
Read more →ZLABof our report on Form 6-K furnished to the SEC on
Zai Lab Limited Supplemental and Updated Disclosures We recently filed a listing application with The Stock Exchange of Hong Kong Limited, or the Hong Kong Stock Exchange, in connection with a proposed secondary listing, or the Listing, of our ordinary shares, par value US$0.000
Read more →ZLABZai Lab Limited Index to Consolidated Financial Statements ​ ​ ​ ​ Page ​ ​ ​ Report of Independent Registered Public Accounting Firm ​ F- 2 Consolidated Balance Sh
2020-12-312029-12-316823724774882338P1YP5YP5Y0.200.20P1Y0.250.25 Index to Consolidated Financial Statements Page Report of Independent Registered Public Accounting Firm F- 2 Consolidated Balance Sheets as of December 31, 2019 and June 30, 2020 F- 4 Consolidated Statements o
Read more →ZLABZai Lab Announces NMPA Approval of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China - ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line a
Zai Lab Announces NMPA Approval of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China - ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of b
Read more →ZLABTurning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
Read more →ZLABZai Lab Appoints F. Ty Edmondson as Chief Legal Officer SHANGHAI and
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer SHANGHAI and SAN FRANCISCO, August 17, 2020 -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that F. Ty Edmondson has been named Chief Legal Officer. Mr. Edmondson
Read more →ZLABZai Lab Announces Financial Results for Six Months Ended
Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates -- Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT -- -- Recent highlights include successful ZEJULA and Optune commercial launches, NMPA approval for Optune, two hig
Read more →ZLABChina NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have re
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, in
Read more →ZLABTURNING POINT THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR REPOTRECTINIB IN GREATER CHINA Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to
TURNING POINT THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR REPOTRECTINIB IN GREATER CHINA Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milest
Read more →ZLABChina NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clin
China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding O
Read more →ZLABRegeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland C
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau Collaboration will also support enroll
Read more →ZLABZai Lab Announces Financial Results for Full Year Ended
Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates -- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT SHANGHAI, China, and SAN FRANCISCO, March 19, 2020 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based inn
Read more →ZLABZai Lab Announces Acceptance of sNDA Submission of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA SHANGHAI, China, and
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA SHANGHAI, China, and SAN FRANCISCO, March 16, 2020 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial st
Read more →ZLABZai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option SHANGHAI, China, and
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option SHANGHAI, China, and SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), a China and U.S.-based innovative
Read more →ZLABZai Lab Announces Pricing of Public Offering of American Depositary Shares
Zai Lab Announces Pricing of Public Offering of American Depositary Shares SHANGHAI, China, January 22, 2020 (GLOBE NEWSWIRE) Zai Lab Limited ( Zai Lab or the Company ) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced
Read more →ZLABZai Lab Appoints Lonnie Moulder to Board of Directors
Zai Lab Appoints Lonnie Moulder to Board of Directors SHANGHAI, China, and SAN FRANCISCO, January 14, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Lonnie
Read more →ZLABZai Lab Announces NMPA Approval of ZEJULA (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer ZEJULA is a potential best-in-class PARP inhibitor for ovarian cancer patients due to its c
Zai Lab Announces NMPA Approval of ZEJULA (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer ZEJULA is a potential best-in-class PARP inhibitor for ovarian cancer patients due to its compelling clinical data1, once-daily dosing and pharmacokin
Read more →ZLABZai Lab Announces Financial Results and Corporate Update for the Six Months Ended
Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 -- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT-- SHANGHAI, China and SAN FRANCISCO, Sep. 3, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or "the Company
Read more →ZLABIncyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China Zai Lab to host Webcast & Conference Call to discuss the collaboration and license agreement on July 2
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China Zai Lab to host Webcast & Conference Call to discuss the collaboration and license agreement on July 2nd at 8:30am EDT WILMINGTON, Del. and SHANGHAI, China - July 2, 2019 - Incyte (N
Read more →ZLABDeciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China - Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China - - Decip
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China - Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China - - Deciphera To Receive $20 Million Upfront Cash Payment, up to $1
Read more →ZLABZai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer Appointment of Industry Veteran Further Enhances Company's Internal Discovery Capabilities and U.S. Presence Shanghai, China and San Francisco, CA
Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer Appointment of Industry Veteran Further Enhances Company's Internal Discovery Capabilities and U.S. Presence Shanghai, China and San Francisco, CA, June 3, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB
Read more →ZLABLEGAL OPINION To: Zai Lab Limited 4560 Jinke Road Bldg. 1, 4F, Pudong, Shanghai People's Republic of China
1, 4F, Pudong, Shanghai "PRC Subsidiaries" mean Zai Lab (Shanghai) Co., Ltd., Zai Lab (Suzhou) Co., Ltd. and Zai Biopharmaceutical (Suzhou) Co. Limited. "PRC Laws" means any and all laws, regulations, statutes, rules, decrees, notices, and supreme court's judicial interpretation
Read more →ZLABSHANGHAI, China
SHANGHAI, China, May 1, 2019 (GLOBE NEWSWIRE) - Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 5,000,000 American
Read more →ZLABZai Lab Announces Financial Results and Corporate Update for Full Year 2018 -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. EST
Zai Lab Announces Financial Results and Corporate Update for Full Year 2018 -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. EST-- SHANGHAI, China, Mar. 7, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai lab" or the Company) (NASDAQ: ZLAB), a China and US-based
Read more →ZLABZai Lab added into the NASDAQ Biotechnology Index
Zai Lab added into the NASDAQ Biotechnology Index
Read more →ZLABZai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the
Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA SHANGHAI, China, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced that the
Read more →ZLABMacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT Molecule in Greater China - Comprehensive collaboration across three MacroGenic
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT Molecule in Greater China ROCKVILLE, MD, and SHANGHAI, China, Nov. 29, 2018 (GLOBE NEWSWIRE) - MacroGenics (NASDAQ: MGNX), a clinical-stag
Read more →ZLABZai Lab Announces Approval of ZEJULA (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong ZEJULA is the first and only PARP inhibitor approved in Hong Kong for the maintenance treatment of platinum-sensitiv
Zai Lab Announces Approval of ZEJULA (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong ZEJULA is the first and only PARP inhibitor approved in Hong Kong for the maintenance treatment of platinum-sensitive relapsed ovarian cancer irrespective of BRCA mutation sta
Read more →ZLABZai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence Mr. Fu will oversee global business development, discovery, manufacturing and other operational activities in newly-crea
Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence Mr. Fu will oversee global business development, discovery, manufacturing and other operational activities in newly-created role Mr. Fu will lead expansion of U.S. operations and
Read more →ZLABNovocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, inclu
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune , in China, Hong Kong, Macau and
Read more →ZLABZai Lab Announces Financial Results and Corporate Progress for the Six Months ended
Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 SHANGHAI, China, August 30, 2018 (GLOBE NEWSWIRE) Zai Lab Limited ( Zai Lab or the Company ) (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced
Read more →ZLABZai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors
Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors SHANGHAI, China, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Professor Kai-Xian Chen, Ph.D., was appointed
Read more →ZLABZai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer
Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer SHANGHAI, China, June 05, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that William Liang has been app
Read more →ZLABZai Lab Reports Full Year 2017 Financial Results and Corporate Update -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. ET
Zai Lab Reports Full Year 2017 Financial Results and Corporate Update -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. ET-- SHANGHAI, China, May 2, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, to
Read more →ZLABEntasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514 Collaboration will facilitate enrollment of pivotal global Phase 3 trial of
Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514 Collaboration will facilitate enrollment of pivotal global Phase 3 trial of ETX2514 in combination with sulbactam for the treatment
Read more →ZLABZai Lab Limited to Announce Full Year 2017 Financial Results
Zai Lab Limited to Announce Full Year 2017 Financial Results SHANGHAI, China. April 24, 2018: Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, May 2nd, 2018 at 8:
Read more →ZLABZai Lab Limited Appoints Billy Cho as Chief Financial Officer
Zai Lab Limited Appoints Billy Cho as Chief Financial Officer SHANGHAI, China. March 5, 2018: Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the appointment of Billy Cho as Chief Financial Officer. Mr. Cho joins from Citig
Read more →ZLABDisclaimer This presentation includes forward-looking statements, beliefs or opinions, including statements with respect to our business, financial condition, results of operations and plans. These forward-looking statem
JP Morgan Healthcare Conference 2018 NASDAQ: ZLAB Exhibit 99.1 Disclaimer This presentation includes forward-looking statements, beliefs or opinions, including statements with respect to our business, financial condition, results of operations and plans. These forward-looking
Read more →ZLABFive Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration Planned global Phase 3 FIGHT trial in front-line ga
Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Planned global Phase 3 FIGHT trial in front-line gastric and gastro-esophageal junction cancers to include sites in China wh
Read more →ZLABZai Lab Limited Announces Closing of U.S. Initial Public Offering of ADSs
Zai Lab Limited Announces Closing of U.S. Initial Public Offering of ADSs
Read more →ZLABZai Lab Limited Announces Pricing of U.S. Initial Public Offering of ADSs
Zai Lab Limited Announces Pricing of U.S. Initial Public Offering of ADSs
Read more →ZLABZai Lab Secures Series C Financing
Zai Lab Secures Series C Financing
Read more →ZLABParatek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China
Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China
Read more →ZLABZai Lab Secures Over $100M Series B Financing from Leading Healthcare Investors
Zai Lab Secures Over $100M Series B Financing from Leading Healthcare Investors
Read more →ZLABZai Lab Of Shanghai Raises Over $30 Million In Series A Funding
Zai Lab Of Shanghai Raises Over $30 Million In Series A Funding
Read more →Competitive Position
How ZLAB ranks across every disease it competes inCompetitive Position is a premium feature
See how ZLAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial